Roche
↗Basel, Switzerland
Roche is a leading Swiss biopharmaceutical and diagnostic company founded in 1896, headquartered in Basel, Switzerland. The company is the fifth-largest pharmaceutical company globally by revenue and the world's leading provider of cancer treatments and in-vitro diagnostics. With 103,249 employees across multiple global sites, Roche operates integrated Pharmaceutical and Diagnostics divisions that serve patients in over 180 countries. The company has expanded significantly through strategic acquisitions, most notably Genentech (acquired 2009), positioning it as a major player in innovative therapeutics spanning oncology, immunology, neurology, and rare diseases.
CLASSIFICATION
Company Type:Pharma
Therapeutic Areas:
Industry:Pharmaceuticals|Biotechnology|Medical Devices|Diagnostics
Sub-Industry:Oncology|Immunology|Neurology|Rare Diseases|Hematology|Infectious Diseases
SIZE & FINANCIALS
Employees:10000+
Revenue:$69.07B (2024 reported)
Founded:1896
Ownership:public
Status:operating
STOCK
Exchange:SIX Swiss Exchange
Ticker:ROG (SIX), RHHBY (OTCQX International Premier)
Market Cap:$328.32B
PIPELINE
Stage:Discovery|Preclinical|Phase 1|Phase 2|Phase 3|Commercial
Lead Drug Stage:Phase III for multiple candidates (fenebrutinib in MS, trontinemab in Alzheimer's)
Modalities:Small molecule, mAb, ADC, Cell therapy, Gene therapy, RNA therapeutics, Bispecific antibodies
Trial Phases:-
FDA Approvals:4
EMA Approvals:3
CORPORATE STRUCTURE
Subsidiaries:Genentech (100% owned), Chugai Pharmaceutical (majority stake)
Key Partnerships:Zealand Pharma - petrelintide co-development (up to $5.3B deal value), Alnylam - zilebesiran for cardiovascular disease, PeptiDream - macrocyclic peptide-radioisotope conjugates, Ionis Pharmaceuticals - RNA-targeting therapies for neurological diseases, KSQ Therapeutics - USP1 inhibitor for precision oncology, PathAI - digital pathology for companion diagnostics, SpliceBio - gene therapy for inherited retinal disease ($216M potential), City Cancer Challenge - cancer care partnership reaching 66.5M people, MediLink Therapeutics - c-MET ADC licensing
COMPETITION
Position:Leader
Competitors:Pfizer, Johnson & Johnson, AbbVie, Merck & Co, Novartis, Sanofi, AstraZeneca, GSK
LEADERSHIP
Key Executives:
Dr. Thomas Schinecker - Chief Executive Officer
Dr. Severin Schwan - Chairman
Dr. Alan Hippe - Chief Financial Officer
Wafaa Mamilli - Chief Digital Officer and Chief Technology Officer
Cristina A. Wilbur - Chief People Officer
Teresa Graham - CEO, Roche Pharmaceuticals
Matt Sause - CEO, Roche Diagnostics
Nina Schwab-Hautzinger - Head of Group Communications (Effective Feb 2026)
Scientific Founders:Fritz Hoffmann-La Roche (founder, 1896)
LINKS
Website:roche.com
LinkedIn:LinkedIn Profile
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Roche. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.